Vertex is also developing a version called VX ... which has a phase 1/2 trial on the go for islet cells in its proprietary Cell Pouch device. The first patient to receive that therapy has now ...

This week, Vertex announced a partnership with Lonza ... also recently reported positive results with its Cell Pouch islet cell transplant system, including insulin independence of between six ...

Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $503.20, representing a -1.37% change from its previous close. Amicus Therapeutics (FOLD) reported earnings 30 days ago.

Please provide your email address to receive an email when new articles are posted on . Nicotine pouches have soared in popularity recently with many users thinking they are harmless. But these ...

A New York state lawmaker is proposing a ban on the sale of what he described as "highly addictive" flavored nicotine pouches, even after the U.S. Food and Drug Administration came out in support ...

A state legislator is moving to outlaw the sale of flavored nicotine pouches, despite the federal Food and Drug Administration’s endorsement of the product’s potential health benefits in ...

Add articles to your saved list and come back to them any time. Nicotine pouches are flavoured sachets designed to be placed between the lip and the gum, delivering nicotine to the body.

France notified the European Commission it will ban sales of nicotine pouches, becoming the latest EU country to push back against the industry that has heavily invested in new and addictive products.